Stifel raised the firm’s price target on Structure Therapeutics (GPCR) to $90 from $50 and keeps a Buy rating on the shares after both of the ACCESS and ACCESS-II trials confirmed aleniglipron’s dose-dependent potency and importantly improved safety profile. Structure “now has a viable and versatile small-molecule offering for independent development or future partnership,” the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Promising Potential of Structure Therapeutics’ Aleniglipron: A Buy Rating Based on Transformative Efficacy and Strategic Innovation
- Structure Therapeutics ACCESS data validates ‘bull case,’ says H.C. Wainwright
- Positive Outlook for Structure Therapeutics: Aleniglipron Shows Promising Results in Obesity Treatment
- Structure Therapeutics rises 101.6%
- Midday Fly By: IBM to buy Confluent, Paramount goes hostile for Warner Bros.